Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Aug 14, 2014; 20(30): 10419-10424
Published online Aug 14, 2014. doi: 10.3748/wjg.v20.i30.10419
Published online Aug 14, 2014. doi: 10.3748/wjg.v20.i30.10419
Proton pump inhibitor responsive esophageal eosinophilia, a distinct disease entity?
William Munday, Department of Pathology, Yale University School of Medicine, New Haven, CT 06520, United States
Xuchen Zhang, Department of Pathology, VA Connecticut Health System and Yale University School of Medicine, West Haven, CT 06516, United States
Author contributions: Munday W performed review of the literature and drafted the manuscript; Zhang X provided overall intellectual input into the design and edited the final version of the manuscript; all authors approved the final version to be published.
Correspondence to: Xuchen Zhang, MD, PhD, Department of Pathology, VA Connecticut Health System and Yale University School of Medicine, 950 Campbell Ave. West Haven, CT 06516, United States. xuchen.zhang@yale.edu
Telephone: +1-203-9325711 Fax: +1-203-9374704
Received: January 21, 2014
Revised: March 26, 2014
Accepted: April 30, 2014
Published online: August 14, 2014
Processing time: 209 Days and 8.8 Hours
Revised: March 26, 2014
Accepted: April 30, 2014
Published online: August 14, 2014
Processing time: 209 Days and 8.8 Hours
Core Tip
Core tip: The concept of pump inhibitor responsive esophageal eosinophilia (PPI-REE) is relatively new. The underlying mechanism(s) of PPI-REE pathogenesis and therapeutic effect of the PPI are still unknown. It is currently still unclear if PPI-REE is a subtype of gastroesophageal reflux disease (GERD), an eosinophilic esophagitis (EoE) phenotype, or a distinct entity. The aim of this manuscript is to review the mechanistic data of the proposed immune modulation/anti-inflammatory role of PPI at the esophageal mucosa, and the existence of PPI-REE as a distinct disease entity from GERD and EoE.